0000899243-19-002323.txt : 20190201 0000899243-19-002323.hdr.sgml : 20190201 20190201163848 ACCESSION NUMBER: 0000899243-19-002323 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190131 FILED AS OF DATE: 20190201 DATE AS OF CHANGE: 20190201 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Shannon John Patrick Jr CENTRAL INDEX KEY: 0001553595 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38536 FILM NUMBER: 19560299 MAIL ADDRESS: STREET 1: DURATA THERAPEUTICS, INC. STREET 2: 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR CITY: MORRISTOWN STATE: NJ ZIP: 07960 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: XERIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001346302 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 203352427 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 180 NORTH LASALLE STREET STREET 2: STE 1800 CITY: CHICAGO STATE: IL ZIP: 60601 BUSINESS PHONE: 512-498-2670 MAIL ADDRESS: STREET 1: 180 NORTH LASALLE STREET STREET 2: STE 1800 CITY: CHICAGO STATE: IL ZIP: 60601 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-01-31 0 0001346302 XERIS PHARMACEUTICALS INC XERS 0001553595 Shannon John Patrick Jr C/O XERIS PHARMACEUTICALS, INC. 180 N. LASALLE STREET, SUITE 1810 CHICAGO IL 60601 0 1 0 0 See Remarks Stock Option (right to buy) 13.88 2019-01-31 4 A 0 80000 0.00 A 2029-01-31 Common Stock 80000 80000 D 25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. Executive Vice President and Chief Operating Officer /s/ Beth Hecht, as Attorney-in-Fact 2019-02-01